These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 7918744)
1. Enhanced stability in vitro and in vivo of immunoconjugates prepared with 5-methyl-2-iminothiolane. Carroll SF; Bernhard SL; Goff DA; Bauer RJ; Leach W; Kung AH Bioconjug Chem; 1994; 5(3):248-56. PubMed ID: 7918744 [TBL] [Abstract][Full Text] [Related]
2. Structural features of the antibody-A chain linkage that influence the activity and stability of ricin A chain immunotoxins. Cumber AJ; Westwood JH; Henry RV; Parnell GD; Coles BF; Wawrzynczak EJ Bioconjug Chem; 1992; 3(5):397-401. PubMed ID: 1329989 [TBL] [Abstract][Full Text] [Related]
3. Stability and cytotoxicity of Fab-ricin A immunotoxins prepared with water soluble long chain heterobifunctional crosslinking agents. Woo BH; Lee JT; Park MO; Lee KR; Han JW; Park ES; Yoo SD; Lee KC Arch Pharm Res; 1999 Oct; 22(5):459-63. PubMed ID: 10549572 [TBL] [Abstract][Full Text] [Related]
4. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Knyba RE; Wawrzynczak EJ; Blakey DC Cancer Res; 1987 Nov; 47(22):5924-31. PubMed ID: 3499221 [TBL] [Abstract][Full Text] [Related]
5. New coupling reagents for the preparation of disulfide cross-linked conjugates with increased stability. Arpicco S; Dosio F; Brusa P; Crosasso P; Cattel L Bioconjug Chem; 1997; 8(3):327-37. PubMed ID: 9177838 [TBL] [Abstract][Full Text] [Related]
6. Substituted 2-iminothiolanes: reagents for the preparation of disulfide cross-linked conjugates with increased stability. Goff DA; Carroll SF Bioconjug Chem; 1990; 1(6):381-6. PubMed ID: 2099186 [TBL] [Abstract][Full Text] [Related]
7. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin. Rosenblum MG; Marks JW; Cheung LH Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583 [TBL] [Abstract][Full Text] [Related]
8. Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins. Dosio F; Arpicco S; Adobati E; Canevari S; Brusa P; De Santis R; Parente D; Pignanelli P; Negri DR; Colnaghi MI; Cattel L Bioconjug Chem; 1998; 9(3):372-81. PubMed ID: 9576812 [TBL] [Abstract][Full Text] [Related]
9. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186 [TBL] [Abstract][Full Text] [Related]
10. Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies. Vallera DA; Burns LJ; Frankel AE; Sicheneder AR; Gunther R; Gajl-Peczalska K; Pennell CA; Kersey JH J Immunol Methods; 1996 Oct; 197(1-2):69-83. PubMed ID: 8890895 [TBL] [Abstract][Full Text] [Related]
11. Effect of linkage variation on pharmacokinetics of ricin A chain-antibody conjugates in normal rats. Worrell NR; Cumber AJ; Parnell GD; Mirza A; Forrester JA; Ross WC Anticancer Drug Des; 1986 Nov; 1(3):179-88. PubMed ID: 3502450 [TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications. Foulon CF; Bigner DD; Zalutsky MR Bioconjug Chem; 1999; 10(5):867-76. PubMed ID: 10502355 [TBL] [Abstract][Full Text] [Related]
13. Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants. Thorpe PE; Blakey DC; Brown AN; Knowles PP; Knyba RE; Wallace PM; Watson GJ; Wawrzynczak EJ J Natl Cancer Inst; 1987 Nov; 79(5):1101-12. PubMed ID: 2890786 [TBL] [Abstract][Full Text] [Related]
15. Improved pharmacokinetics and tumor localization of immunotoxins constructed with the Mr 30,000 form of ricin A chain. Trown PW; Reardan DT; Carroll SF; Stoudemire JB; Kawahata RT Cancer Res; 1991 Aug; 51(16):4219-25. PubMed ID: 1868442 [TBL] [Abstract][Full Text] [Related]
17. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and characterization of carbohydrate-linked murine monoclonal antibody K20-human serum albumin conjugates. Kondejewski LH; Kralovec JA; Blair AH; Ghose T Bioconjug Chem; 1994; 5(6):602-11. PubMed ID: 7873663 [TBL] [Abstract][Full Text] [Related]
19. Ricin A immunotoxins of IgG and Fab of anti-CALLA monoclonal antibody: effect of water soluble long-chain SPDP on conjugate yield, immunoselectivity and cytotoxicity. Woo BH; Lee JT; Lee KC Arch Pharm Res; 1994 Dec; 17(6):452-7. PubMed ID: 10319157 [TBL] [Abstract][Full Text] [Related]
20. Purification and properties of immunotoxins containing one vs. two deglycosylated ricin A chains. Ghetie V; Swindell E; Uhr JW; Vitetta ES J Immunol Methods; 1993 Nov; 166(1):117-22. PubMed ID: 8228282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]